McArthur Heather L, Hudis Clifford A
Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Hematol Oncol Clin North Am. 2007 Apr;21(2):207-22. doi: 10.1016/j.hoc.2007.03.008.
Systemic chemotherapy is an integral component of the adjuvant treatment strategy for women who have early-stage breast cancer and accounts for significant improvements in breast cancer-specific mortality. Decisions regarding adjuvant therapy are increasingly complex with the advent of new therapeutic strategies, a growing body of literature on the molecular biology and natural history of breast cancer, and advances in therapeutic techniques and early detection. Ultimately, the risk-benefit calculus will continue to evolve in response to these advances and one hopes that clinicians will soon be able to tailor treatment recommendations to the biology of an individual cancer and the needs of the affected individual.
全身化疗是早期乳腺癌女性辅助治疗策略的重要组成部分，对乳腺癌特异性死亡率的显著改善有重要作用。随着新治疗策略的出现、关于乳腺癌分子生物学和自然史的文献不断增多以及治疗技术和早期检测的进步，辅助治疗的决策日益复杂。最终，风险效益评估将继续随着这些进展而演变，人们希望临床医生很快能够根据个体癌症的生物学特性和患者的需求来定制治疗建议。
